Oncology Biosimilars Market Report 2026

Oncology Biosimilars Market Overview

• Oncology Biosimilars market size has reached to $11.35 billion in 2025 • Expected to grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Patent Expirations Drive New Oncology Biosimilars • Market Trend: Increasing Focus On Investments To Support The Battle Of Cancer • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Oncology Biosimilars Market?

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Oncology Biosimilars Market Growth Forecast?

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to launch of new biosimilar drugs including pembrolizumab and pegfilgrastim, expansion of online pharmacy distribution channels, rising adoption of immunomodulators and hematopoietic agents, increasing government initiatives to improve cancer care access, growing focus on personalized oncology treatment. Major trends in the forecast period include rising adoption of rituximab, trastuzumab, and bevacizumab biosimilars, increasing use of immunomodulators and hematopoietic agents in cancer therapy, growth in g-csf biosimilars for neutropenia management, expansion of hospital and retail pharmacy channels for oncology biosimilars, focus on cost-effective and accessible cancer treatment options.

Global Oncology Biosimilars Market Segmentation

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars 2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars 3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars 4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

What Is The Driver Of The Oncology Biosimilars Market?

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. For instance, in February 2024, according to the DrugTimes is a Chinese-based company focused on the pharmaceutical and biotech industry, by 2037, more than 25 products will lose patent protection, potentially resulting in a combined revenue decline exceeding $236.4 billion, based on 2024 sales figures. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for the oncology biosimilars industry.

Key Players In The Global Oncology Biosimilars Market

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Global Oncology Biosimilars Market Trends and Insights

Major companies operating in the oncology biosimilars market are focusing on developing innovative cancer therapies such as targeted biologics and monoclonal antibodies to enhance treatment efficacy, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are lab-engineered proteins designed to recognize and bind specific cancer cell antigens, enabling precise targeting and immune-mediated destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, merged with Seagen and invested $43 billion to strengthen its oncology portfolio. This strategic move enhances Pfizer’s presence in cancer therapeutics and accelerates the development of advanced treatments against cancer, a leading cause of death worldwide. The investment also underscores the growing trend of significant capital allocation toward innovative oncology biosimilars to address unmet medical needs and expand global access to cancer care.

What Are Latest Mergers And Acquisitions In The Oncology Biosimilars Market?

In October 2024, Teva Pharmaceuticals Inc., an Israel-based pharmaceutical company, formed a partnership with mAbxience, to advance next-generation oncology biosimilar solutions. The collaboration aims to improve access to, and broaden the development of, high-quality oncology biosimilars, enhancing patient outcomes in cancer treatment while fostering innovation and growth in the oncology biologics market. mAbxience S.A. is a a Spain-based biopharmaceutical company focused on the development and commercialization of monoclonal antibody biosimilars.

Regional Insights

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oncology Biosimilars Market?

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oncology Biosimilars Market Report 2026?

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.